Purpose Vesicular monoamine transporters 1 and 2 (VMAT1 and VMAT2) are thought to mediate MIBG uptake in adult neuroendocrine tumors. In neuroblastoma, the norepinephrine transporter (NET) has been investigated as the principal MIBG uptake protein, though some tumors without NET expression concentrate MIBG. We investigated VMAT expression in neuroblastoma and correlated expression with MIBG uptake and clinical features. Methods We evaluated VMAT1 and VMAT2 expression by immunohistochemistry (IHC) in neuroblastoma tumors from 76 patients with high-risk metastatic disease treated in a uniform cooperative group trial (COG A3973). All patients had baseline MIBG diagnostic scans centrally reviewed. IHC results were scored as the product of intensity grading (0 -3+) and percent of tumor cells expressing the protein of interest. The association between VMAT1 and VMAT2 scores and clinical and biological features was tested using Wilcoxon rank-sum tests. Results Patient characteristics were typical of high-risk neuroblastoma, though the cohort was intentionally enriched in patients with MIBG-nonavid tumors (n=20). VMAT1 and VMAT2 were expressed in 62 % and 75 % of neuroblastoma tumors, respectively. VMAT1 and VMAT2 scores were both significantly lower in MYCN amplified tumors and in tumors with high mitotic karyorrhectic index. MIBG-avid tumors had significantly higher VMAT2 scores than MIBG-nonavid tumors (median 216 vs. 45; p=0.04). VMAT1 expression did not correlate with MIBG avidity. Conclusion VMAT1 and VMAT2 are expressed in the majority of neuroblastomas. Expression correlates with other biological features. The expression level of VMAT2 but not that of VMAT1 correlates with avidity for MIBG.
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Introduction
Neuroblastoma is the most common pediatric extracranial solid tumor, with approximately 650 new cases each year in the US [1] . More than half of children with neuroblastoma present with widespread metastatic disease at diagnosis, with a poor probability of long-term survival. Neuroblastoma most commonly presents in the adrenal medulla, but primary tumors can arise elsewhere along any portion of the sympathetic chain. Neuroblastoma primary and metastatic tumors can be detected using an analogue of norepinephrine, metaiodobenzylguanidine (MIBG) tagged with a radionuclide [2] . Low-dose 123 I-MIBG is used diagnostically to localize tumors, while high-dose 131 I-MIBG is used as a targeted radiopharmaceutical [3] . In patients with relapsed or refractory neuroblastoma, high-dose 131 I-MIBG has a response rate of 30 -40 % [4] . Eventually 131 I-MIBG may play a role in the initial treatment of high-risk neuroblastoma, and further understanding of mediators of MIBG uptake by neuroblastoma is critical.
Clinically, 90 % of neuroblastomas are able to accumulate MIBG [5] . The remaining 10 % of patients who present with neuroblastoma tumors that do not accumulate MIBG are currently not candidates for targeted imaging or therapy with MIBG. The norepinephrine transporter (NET) has been shown to facilitate specific uptake of MIBG, a norepinephrine analogue [6] [7] [8] . Clinically, our group and others have shown that there is a significant correlation between tumor NET expression and MIBG accumulation [9] [10] [11] . Our group has also identified tumors that are MIBG-avid but have little or no NET expression, and other tumors that express high levels of NET but do not accumulate MIBG [10] . These findings suggest that there are alternative mechanisms by which MIBG is specifically taken up and/or retained by neuroblastoma.
We hypothesized that the vesicular monoamine transporters (VMATs) might be expressed in neuroblastoma and play a role in mediating MIBG accumulation. VMATs are acidic glycoproteins with 12 transmembrane domains. There are two isoforms, VMAT1 and VMAT2 [12] . VMATs transport monoamine neurotransmitters, including norepinephrine, against their concentration gradient from the cytosol into transport vesicles in the presynaptic neuron. Several pieces of evidence argue that MIBG is a substrate for VMATs. Reserpine, a VMAT inhibitor, hastens MIBG clearance from normal adrenal medulla and pheochromocytoma and reduces MIBG uptake in pheochromocytoma [13, 14, 7] . In neuroendocrine tumors other than neuroblastoma, VMAT expression has been shown to correlate with MIBG uptake [15, 14] .
We conducted a retrospective study to describe VMAT1 and VMAT2 expression in neuroblastoma cell lines and human tumors. We further aimed to correlate VMAT1 and VMAT2 expression with clinical and biological features in patients with high-risk neuroblastoma, including MIBG avidity. Finally, we assessed the association between VMAT1 and VMAT2 expression and NET protein expression in these tumors.
Materials and methods
Western blot for NET, VMAT1, and VMAT2 expression Neuroblastoma and control cells were grown in Iscove's modified Dulbecco's medium with 20 % fetal bovine serum (FBS) + insulin-transferrin-selenium medium or in Dulbecco's modified Eagle's medium with 10 % FBS. HEK293T cells transfected to overexpress VMAT1, VMAT2, NET, or empty vector served as controls. Cells were harvested, lysed with Cell Signaling lysis buffer + 1 % sodium dodecyl sulfate and sonicated, and the supernatants were boiled in lithium dodecyl sulfate sample buffer (Invitrogen). Protein was quant itated using the bicinchoninic acid assay (Pierce) and analyzed on 4 -12 % gradient Bis-Tris gels (Invitrogen). Membranes were incubated overnight at 4°C with primary antibodies [VMAT1 (abcam), VMAT2 (OriGene), hNET (MAb Technologies), MYCN (abcam), MYC (Cell Signaling), and GAPDH (Millipore)], then developed using horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling) and ECL reagents (Amersham).
Patients and MIBG diagnostic scans
All patients had high-risk metastatic neuroblastoma and participated in Children's Oncology Group (COG) trial A3973 [16] . All patients were unique from our prior cohort [10] , except one MIBG-nonavid patient was included in both cohorts. Pathology, ploidy, 1p and 11q status, and MYCN copy number were determined in the COG central reference laboratory. Patients underwent diagnostic 123 I-MIBG or 131 I-MIBG whole-body scans at the time of study entry. Scans were obtained according to local institutional practice. Baseline diagnostic MIBG scans were available for central review for all patients included in this analysis [17] . The primary clinical endpoint for the current study, MIBG avidity, was based upon the results of this independent central review that preceded determination of tumor transporter expression levels in the current study. Among patients with MIBG-avid tumors, the intensity of MIBG avidity was not scored. This retrospective study was approved by the Committee on Human Research at the University of California, San Francisco.
Immunohistochemistry for NET, VMAT1, and VMAT2 protein expression
Unstained slides of paraffin-embedded tumor material were obtained from the COG Neuroblastoma Reference Laboratory (Nationwide Children's Hospital, Columbus, OH). Slides were selected by the staff at the reference laboratory and sent to UCSF for testing. For NET staining, slides were stained with commercially available NET antibody (NET17-1; MAb Technologies; Stone Mountain, GA) at a 1:2,000 dilution. Antigen was detected using an avidin-biotinylated enzyme complex (ABC detection; commercial kit). Positive controls included pheochromocytoma and human embryonic kidney (HEK) cells transfected with NET. Negative controls included pheochromocytoma with no primary antibody added and tonsil.
For VMAT1 staining, slides were heated at 60°C for 30 min prior to staining. They were then deparaffinized and rehydrated, then placed in a pressure cooker in 10 mM citrate buffer. The slides were incubated with VMAT1 rabbit polyclonal antibody (Phoenix Pharmaceuticals; H-V001, 1:500 dilution) overnight at 4°C, and then with a HRP-conjugated secondary antibody for 30 min at room temperature. Lastly, the slides were incubated with diaminobenzidine using a highsensitivity substrate chromogen system (Dako, Carpinteria, CA). Positive controls included pheochromocytoma and HEK cells transfected to express VMAT1. Negative controls included tonsil, HEK cells transfected with empty vector, HEK cells transfected to express VMAT1 with no primary antibody added, and pheochromocytoma with no primary antibody added.
For VMAT2 staining, slides were prepared and stained as for VMAT1 except that a VMAT2 mouse IgG1 monoclonal antibody (Origene TA500506, clone 9E11, 1:400 dilution) was used. Positive controls included pheochromocytoma and HEK cells transfected to express VMAT2. Negative controls included tonsil, HEK cells transfected with empty vector, HEK cells transfected to express VMAT2 with no primary antibody added, and pheochromocytoma with no primary antibody added.
Each slide was reviewed by two of three investigators (a pediatric pathologist, G.K., for all slides, and either W.T. or L.M. as second reviewer), with consensus results used for analysis. Investigators were blinded to patient clinical and biological features at the time of slide review. Stains were assigned a semiquantitative intensity value of 0 to 3+ for tumor cell staining. In the event of heterogeneous staining, the higher intensity category was coded as long as at least 5 % of cells were stained in this category. The percent of tumor cells expressing the protein of interest was also recorded. A composite protein expression score was calculated as the simple product of the intensity score and the percent of positive tumor cells.
Statistical analyses
We used a series of Wilcoxon rank-sum tests to compare VMAT1 and VMAT2 composite protein scores between patient groups defined by clinical and biological features of interest including MIBG avidity (avid vs. nonavid), age at diagnosis (dichotomized at 18 months), primary site (adrenal vs. other), MYCN status (amplified vs. not amplified), tumor ploidy (hypodiploid or diploid vs. hyperdiploid), International Neuroblastoma Pathology Classification (INPC) histology classification (favorable vs. unfavorable) [18] , mitotic karyorrhectic index (MKI; low/intermediate or 0 -4 % vs. high or >4 %), tumor grade (differentiating vs. poorly differentiated or undifferentiated), catecholamine status at diagnosis (elevated vs. not elevated), 1p status (loss of heterozygosity, LOH, vs. no LOH), and 11q status (aberration vs. no aberration).
As we had a particular interest in the association between VMAT expression and MIBG avidity, we also used Wilcoxon rank-sum tests to compare percent tumor cells positive for VMAT1 or VMAT2 between MIBG-avid and MIBGnonavid tumors. We also used Fisher's exact tests to determine whether VMAT protein expression intensity categories were associated with MIBG avidity. The degree of statistical dependence between NET and VMAT1 and VMAT2 levels was assessed by calculating Spearman rank correlation coefficients. Scatter plots with best-fit lines were produced to accompany these correlative tests.
Results

VMAT1 and VMAT2 expression in neuroblastoma cell lines
We first assessed the range of VMAT1 and VMAT2 protein expression in neuroblastoma cell lines (Fig. 1) . All cell lines expressed VMAT1, a subset expressed VMAT2, and the majority expressed NET. There was no clear pattern of expression based on MYCN amplification status, MYC protein expression, or NET expression.
VMAT1 and VMAT2 expression in neuroblastoma tumors
Of the 82 patients evaluated, 6 had samples with inadequate tumor material for assessment of VMAT1 or VMAT2 expression, due to crush artifact, necrotic tumor, or insufficient tumor cells. The characteristics of the 76 patients with evaluable samples are shown in Table 1. VMAT1 and VMAT2 were expressed in 62 % and 75 % of neuroblastoma tumors, respectively. Representative immunohistochemistry (IHC) images are shown in Supplementary Fig. 1 . VMAT2 staining intensity was 3+ in 55 % of tumors and VMAT1 staining intensity was 3+ in 32 % of tumors. The distribution of VMAT1 and VMAT2 composite protein expression scores is shown in Fig. 2a . Both proteins showed a wide range of expression between individual tumors. The median VMAT2 composite expression score was higher than the median VMAT1 composite expression score (153 vs. 47). VMAT1 and VMAT2 expression scores showed a moderate correlation (Supplementary Fig. 2 ; correlation coefficient 0.66, p<0.001), although there were tumors with intense VMAT2 expression that did not express VMAT1.
VMAT1 and VMAT2 expression correlates with clinical and biological features in patients with high-risk neuroblastoma
Correlations between VMAT1 and VMAT2 composite protein expression scores and clinical and biological features are shown in Table 1 . VMAT1 and VMAT2 protein expression scores were significantly lower in MYCN-amplified tumors and in tumors with high MKI. In addition, VMAT2 protein expression scores were significantly lower in hypodiploid/ diploid tumors and tumors without 11q aberration. There was a trend to suggest lower VMAT2 expression in tumors from patients <18 months of age at diagnosis and in nonadrenal primary tumors.
VMAT2 expression correlates with MIBG avidity
Given their role as monoamine transporters, we were particularly interested in evaluating whether VMAT1 and/or VMAT2 protein expression correlate with MIBG avidity based upon diagnostic MIBG scans. VMAT1 expression intensity category, percent of cells positive for VMAT1, and VMAT1 composite expression score were not associated with MIBG avidity (Table 2 , Fig. 2b ). For VMAT2, expression intensity category was not significantly associated with MIBG avidity. However, MIBG-avid tumors had significantly higher VMAT2 composite expression scores than MIBG-nonavid tumors, although there was substantial overlap between groups (median 216 vs. 45, p=0.04; Table 2 , Fig. 2c ). There was also a trend to suggest that MIBG-avid tumors had a higher percent of cells positive for VMAT2 protein expression than MIBGnonavid tumors (median 74 % vs. 18 %, p=0.05).
VMAT1 and VMAT2 expression correlates with NET expression
As NET protein expression plays a key role in MIBG avidity, we next evaluated whether VMAT1 and VMAT2 protein expression correlates with NET protein expression. We observed a weak correlation between VMAT1 and NET protein expression, although all of the tumors with intense VMAT1 expression had at least moderate NET expression ( Fig. 3a ; correlation coefficient 0.46, p<0.001). There was a greater degree of correlation between VMAT2 and NET protein expression, particularly at the upper end of expression ( Fig. 3b ; correlation coefficient 0.67, p<0.001).
Our previous work demonstrated that MYCN-amplified tumors show lower NET protein expression than MYCN nonamplified tumors [10] . The current project allowed us to validate this finding in an independent dataset (with only one patient with a MIBG-nonavid tumor in common with our prior analysis). We again observed that MYCN-amplified tumors had lower NET composite protein expression scores than MYCN non-amplified tumors (median 80 vs. 195, p=0.007). 
Discussion
To our knowledge, this is the first study to examine the correlation between the expression of the two VMAT isoforms and MIBG avidity in human neuroblastoma tumors. We found a positive correlation between VMAT2 expression and MIBG tumor avidity. We found no association between VMAT1 protein expression and MIBG tumor avidity. Our investigations also revealed several associations between other features of neuroblastoma and VMAT protein expression. VMAT1 and VMAT2 proteins had significantly lower levels of expression in neuroblastoma tumors with MYCN amplification and in tumors with high MKI. NET has traditionally been thought to be the primary transporter responsible for MIBG uptake. Our group has previously found a positive correlation between NET expression and MIBG avidity in neuroblastoma tumors, although there was substantial overlap between NET protein expression levels in MIBG-avid and MIBG-nonavid tumors [10] . This finding suggested the possibility that NET may not be the only protein mediating MIBG avidity. Previous studies have already implicated VMAT1 and VMAT2 in MIBG transport in other neuroendocrine tumors [15, 14] . Until now, this phenomenon has remained unstudied in patients with neuroblastoma. The positive statistical association we observed between VMAT2 expression and MIBG avidity is not only consistent with our current understanding of the function of VMAT in neuroendocrine tumors, but also suggests that VMAT2 may also mediate MIBG avidity in neuroblastoma tumors.
Our investigations also revealed strong correlations between VMAT expression and other features of neuroblastoma. While we have previously shown that MYCN-amplified tumors have lower NET protein expression [10] , until now, no studies have evaluated the relationship between VMAT protein expression and tumor biology. Here, we found a significant association between MYCN amplification and low levels of VMAT1 and VMAT2 expression. Taken together with our previous findings, these results suggest a general pattern of lower membrane transporter expression in MYCN-amplified tumors, perhaps as a marker of overall reduced neural differentiation in these tumors. Given this pattern, one might hypothesize that MYCN-amplified tumors are more likely to be MIBG-nonavid, although, to our knowledge, there are no data to support this hypothesis.
We also found lower VMAT protein expression in tumors with high MKI. VMAT2 protein expression was also significantly higher in hyperdiploid tumors and in tumors with an 11q aberration. We observed a trend toward higher VMAT2 protein expression in adrenal primary tumors. VMAT1 and VMAT2 are known to be highly expressed in normal adrenal medullary tissue [19] [20] [21] , although this expression in normal tissue should not have affected our results in adrenal neuroblastoma as only expression on tumor cells was scored in our study. It is unlikely that this pattern was confounded by the association between MYCN amplification and VMAT2 expression as adrenal primary tumors have the highest rates of MYCN amplification [22] , a pattern which should lead to overall lower levels of VMAT2 protein in adrenal tumors. In contrast, it is possible that the other observed associations between VMAT expression and MKI, ploidy, and 11q status are due to the known effects of MYCN status on these features [23, 24] .
We acknowledge certain limitations in our work. We provide statistical correlations between VMAT expression and clinical/biological features of high-risk neuroblastoma. Future studies are required to examine possible mechanisms behind these associations to determine if they are causally linked. Although we did find statistically significant correlations between VMAT expression, MIBG avidity and aspects of tumor biology in neuroblastoma, we also noted a wide range of VMAT1 and VMAT2 expression resulting in substantial overlap between groups. It is not clear if this overlap was a function of the IHC assays or represented the underlying heterogeneity of these tumors. Furthermore, since VMAT1 and VMAT2 expression both positively correlate with NET expression, we concede the possibility that our results may be have been due to the relationship between NET, neuroblastoma tumor biology and MIBG avidity. In addition, as our patient population was chosen specifically to target patients with high-risk stage 4 disease, as this is the target population for MIBG therapy, we were unable to determine whether these results could be generalized to patients with low intermediaterisk or localized high-risk disease. We evaluated only one tumor per patient and cannot speak to whether the results in that tumor are representative of all of the patient's sites of disease involvement. Likewise, within a tumor itself, we were not able to determine the site from which the biopsy was obtained and whether that portion of the tumor showed avidity for MIBG. As these proteins may be expressed heterogeneously throughout a tumor, it is possible that we may have analyzed some tumor samples that were partially MIBGnonavid. Despite these limitations, our work is novel and we describe new correlations between VMAT expression and clinical and biological features in neuroblastoma. Our study benefited from a uniform patient population (all patients had high-risk stage 4 disease), and a relatively large sample size given the rarity of neuroblastoma. The use of multiple reviewers to grade the IHC results as well as uniform central review of all MIBG scans would both have contributed to the quality of our data.
Our work should motivate future studies of several key areas. Future studies will need to investigate potential mechanistic links between VMAT2 expression and MIBG avidity, including whether VMAT2 mediates primary MIBG transport, MIBG retention in tumor cells, or a combination of both roles. Moreover, the interaction between MYCN status and expression of other markers of neural differentiation merits further investigation. Studies investigating the role of signaling pathways, transcriptional factors, and posttranslational factors important in the regulation of the VMAT proteins will be key to understanding why expression of these transporters is linked to other aspects of neuroblastoma tumor biology. From a clinical perspective, it will be of interest to evaluate whether VMAT2 expression correlates with response to MIBG therapy. Such studies will yield results important to expanding our current understanding of how MIBG therapy works, and improving this therapy in neuroblastoma patients. U10CA180899, and U24CA114766. The funding sources did not play a role in study design, conduct, data analysis, or interpretation.
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